[Use of coronaroactive agents with beta-stimulating effect in ischemic heart disease].
In feline experiments and 65 clinical cases of ischaemic heart disease the efficacy of a new beta-stimulating agetn -- Ildamen -- was studied, the obtained effect was compared to that of Euphillin. Ildamen was found to be highly effective in patients with a moderately decreased coronary reserve and without atherosclerotic lesions in the coronary vessels.
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000628:Aminophylline / Q000627:therapeutic use; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D002908:Chronic Disease; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010099:Oxyfedrine / Q000627:therapeutic use*; D011427:Propiophenones / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D000318:Adrenergic beta-Agonists; D011427:Propiophenones; D014665:Vasodilator Agents; D000628:Aminophylline; D010099:Oxyfedrine
O primenenii koronaroaktivnykh sredstv s beta-stimuliruiushchim effektom u bol'nykh ishemicheskoĭ bolezn'iu serdtsa